29 MAR. 2024
Strategic collaboration with Sartorius
- LFB BIOMANUFACTURING will outsource cell line development service to Sartorius to combine the best of each company’s expertise and increase value for customers,
- Collaboration provides single-stop solution for customers to speed up protein therapy development,
- LFB BIOMANUFACTURING specializes in therapeutic protein biomanufacturing, and is an entity of LFB, a leading European company providing plasma-derived medicinal products to healthcare professionals,
The life science group Sartorius and LFB BIOMANUFACTURING, an expert CDMO in the development and manufacture of recombinant proteins, have announced an agreement under which LFB BIOMANUFACTURING will outsource cell line development (CLD) services to Sartorius. To this end, LFB BIOMANUFACTURING and Sartorius have built a strategic partnership to provide joint customers with end-to-end solutions from CLD services to clinical manufacturing, combining each company’s expertise to accelerate therapy development and increase value for customers.
CLD services requires significant expertise and resources and is often outsourced as a result. To bring a project from early discovery to investigational new drug application, biopharmaceutical developers need a partner with comprehensive experience in scale-up, commercialization, the evolving regulatory landscape, and technology transfer.
Through this collaboration, customers will have access to high-performing Sartorius cell lines and media that support successful transfer and scale-up, along with an integrated drug development process from LFB BIOMANUFACTURING. By partnering, the companies are enabling a one-stop solution that reduces the logistic and administrative efforts involved when engaging with multiple stakeholders, streamlining development and manufacturing processes.